Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026

About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

[{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal Phase 3 WU-KONG28 Study of ZEGFROVY® selected as Late-Breaking Abstract","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Oral presentation for DZD6008, the 4th generation EGFR TKI, in EGFR mutated NSCLC after Tagrisso and other 3rd generation EGFR TKI treatment","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Poster presentation on clinical benefits of golidocitinib in combination with PD-1","length":82,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":301,"olType":false},{"type":"text","content":"SHANGHAI, April 21, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced that new clinical data from its non-small cell lung cancer (NSCLC) pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago. The presentations will feature the company's investigational assets ZEGFROVY® (sunvozertinib), golidocitinib, and DZD6008, highlighted by two oral presentations, including one selected as a Late-Breaking Abstract (LBA).","length":613,"tagName":"p"},{"type":"image","alt":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","displaySize":"","headline":null,"caption":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":153,"url":"https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wsIhVBDeioPd1hfwbvilSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3MA--/https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd","width":400,"height":153}},"href":"https://mma.prnewswire.com/media/2084187/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Results from the multinational Phase 3 WU-KONG28 study of ZEGFROVY have been selected for oral presentation as an LBA. ZEGFROVY is an oral, irreversible, and highly selective EGFR tyrosine kinase inhibitor (TKI), approved in China and the U.S. for the treatment of relapsed or refractory NSCLC harboring EGFR exon20ins. WU-KONG28 is a phase 3 randomized pivotal study comparing sunvozertinib vs. chemo doublet in previously untreated NSCLC patients with EGFR exon20...

More updates from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A